Skip to main
NBTX

Nanobiotix SA (NBTX) Stock Forecast & Price Target

Nanobiotix SA (NBTX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nanobiotix is a promising company with a strong focus on revolutionizing medicine through their proprietary nanotechnology. The company has a large market opportunity with their Nanoradioenhancer platform, Nanoprimer platform, and Neurological disease platform. Their lead product candidate, JNJ-1900, is showing promising results in multiple solid tumor indications and has the support of a global pharmaceutical partner. With upcoming pivotal results and partnership updates, there is significant potential for upside in this stock.

Bears say

Nanobiotix is facing challenges with logistics in practice, has high execution and financial risk, as well as the possibility of dilutive financing. The company also relies heavily on milestones for revenue and faces competition in the market. With a current valuation of $36 per ADR based on a DCF analysis, there is potential for downside risks, including disappointing product launches and clinical trial failures. Additional risks include legal issues and government regulations.

Nanobiotix SA (NBTX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nanobiotix SA (NBTX) Forecast

Analysts have given Nanobiotix SA (NBTX) a Buy based on their latest research and market trends.

According to 3 analysts, Nanobiotix SA (NBTX) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nanobiotix SA (NBTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.